

ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS

XXVI Giornate Cardiologiche Torinesi

IN CARDIOLOGY

Directors Fiorenzo Gaita Sebastiano Marra

Turin October 23-25, 2014 Galleria D'Arte Moderna Centro Congressi Unione Industriale di Torino


Smart phones and remote monitoring in preventive cardiology Amir Lerman, MD Professor of Medicine Chair for Research Cardiovascular Division Mayo Clinic, Rochester, MN

Future Vision


- Improve patients' care and global health
- Increase the number of the patients in the Mayo network
- Retain the patients in the system
- Reduce re hospitalization









©2013 MFMER | 3301614-3



- Myocardial ischemia
- Arrhythmias
- Heart failure
- FDA apporval








Background Information

- In 2012, 785,000 Americans will have a new acute coronary syndrome, and 470,000 will have a recurrent coronary attack
- Patients who survive acute stage of an MI have a chance of illness and death 1.5 to 15 times higher than that of general population
 - Among these people, risk of another MI, sudden death, AF, HF and stroke – for both men and women – is substantial (FHS, NHLBI)
- Estimated cost of CHD in 2010 \$177.1 billion
- Re-hospitalization rates are 20-50% (PREMIER registry; Can J Cardiol. 2003)
 - 24-26% readmission rate at 30 days (JAMA, 2011)




Determinants of Health and Their Contribution to Premature Death Proportional Contribution to Premature Death



Schroeder: NEJM 357:1221, 2007




Numbers of U.S. Deaths from Behavioral Causes – 2000





Schroeder SA: NEJM 357:1221, 2007

Adherence to AHA 2020 Recommendations



MAYO CLINIC ŢŢ

(Go, AS, et al. *Circulation*. 2014)

Self Monitoring Platform

Primary prevention

Cardiac rehabilitation post PCI and ACS




The Design of the Application Mayo expertise **Guidelines ACC/AHA/EDC h**ealarium Health organization IN ORANGE 3G 2:56 PM ◎ \$ 94% Home **Funding: BIRD Foundation** Large employee 2 S 0 2 2 2 Shared IPs My Health Tasks Targets 100 Updates The Patients **Plan Adherence** Good Adherence Reward system LDL Cholesterol Reach LDL Choleste.. Social network MAYO CLINIC

Personalized Digital Health Application








Schematic displaying the smartphone (left) and online (right) versions of the cardiac rehabilitation program currently being used in a randomized controlled trial.

Dietary Tasks, example



MAYO CLINIC

Primary and Secondary Prevention Studies

Primary prevention:

- One site 500 individuals 3 months follow up
- Multiple sites 37,000 individuals follow up 1 year

Secondary prevention following ACS

- During the 3 months of cardiac rehabilitation
- During the 3 months following completion of the cardiac rehabilitation



Use of Personalized Digital Health in Primary Prevention

- Employer-implemented incentive plan to motivate healthier employees in coordination with CareHere LLC.
- All participants required to complete the following:
 - Biometric screening and questionnaire regarding personal health
 - 90 day follow-up
- Biometric benchmarks met:
 - Assign to Healthy Benefit Plan/eligible for incentive
- Biometric benchmarks not met:
 - Plan of care created with provider and completed through CareHere Connect
 - Return for 90 day follow up



Demographics

Category	Eligible, Completing (n=508)	Excluded (n=772)	Eligible, Not Initiating (n=127)	Eligible, Not Completing (n=201)	Total (n=1608)
Age (yrs)	46.5 <u>+</u> 11.1	42.2 <u>+</u> 12.0	46.1 <u>+</u> 11.2	46.0 <u>+</u> 12.5	44.3 <u>+</u> 11.9
Female	382 (75%)	630 (82%)	91 (72%)	135 (67%)	1238 (77%)
Caucasian	389 (77%)	581 (75%)	95 (75%)	148 (74%)	1213 (75%)
Smokers	3 (0.01%)	5 (0.01%)	30 (24%)	23 (11%)	61 (4%)
Htn Rx	135 (27%)	80 (10%)	26 (20%)	41 (20%)	282 (18%)
DM Rx	25 (5%)	8 (1%)	3 (2%)	5 (3%)	41 (3%)
HLD Rx	39 (8%)	21 (3%)	6 (5%)	10 (5%)	76 (5%)





Using an online, personalized program reduces cardiovascular risk factor profiles in a motivated, adherent population of participants

R. J. Widmer, MD, PhD, ^a Thomas G. Allison, PhD, ^a Brendie Keane, RN, ^c Anthony Dallas, MD, ^c Lilach O. Lerman, MD, PhD, ^b and Amir Lerman, MD ^a *Rocbester, MN and Nasbville, TN*


Methods: A cohort of employees in Tennessee was subjected to a health risk assessment at baseline. Those who did not meet all 5 healthy benchmarks – body mass index, blood pressure, glucose, total cholesterol and smoking status – were prospectively assigned to a web-based personal health assistant and had repeat measurements taken at 90 days

Reductions in Raw FRS (left) and Converted FRS 10-year cardiovascular risk percentage (right)





Percent Change from Baseline in Risk Factors After Completing the Online PHA






Use of Personalized Digital Health in Primary Prevention: multi center study


- To prospectively follow a large cohort of employees across multiple employers in an effort to
 - 1) Validate the previously studies DHI in a larger population
 - 2) Study potential factors associated with patterns in adherence or success in reducing CVD risk factors with this particular WHP DHI.





Category	Non- Participant (n=14,173)	Low- Participant (n=14,304)	High- Participant (n=2,381)	Total
Age (yrs)	47.7 <u>+</u> 12.2	48.4 <u>+</u> 11.2	48.1 <u>+</u> 11.3	48.1 <u>+</u> 11.7
Weight (lbs)	196.3 <u>+</u> 50.0	198.8 <u>+</u> 50.9	195.8+ 49.2	197.4 <u>+</u> 50.4
Waist Circ (in)	36.8 <u>+</u> 6.2	38.0 <u>+</u> 6.5	37.6+ 6.3	37.4 <u>+</u> 6.4
BMI (kg/m²)	30.1 <u>+</u> 6.7	31.2 <u>+</u> 7.1	30.7+ 6.7	30.7 <u>+</u> 6.9
Systolic BP (mmHg)	123.6 <u>+</u> 14.5	123.3 <u>+</u> 14.0	122.6 <u>+</u> 13.3	123.4 <u>+</u> 14.2
Diastolic BP (mmHg)	77.7 <u>+</u> 9.7	77.8 <u>+</u> 9.2	77.7 <u>+</u> 9.0	77.8 <u>+</u> 9.4
Triglycerides (mg/dL)	130.8 <u>+</u> 80.2	139.4 <u>+</u> 81.5	135.0 <u>+</u> 75.9	134.7 <u>+</u> 80.6
LDL (mg/dL)	111.2 <u>+</u> 32.0	111.9 <u>+</u> 32.5	110.5 <u>+</u> 32.1	111.5 <u>+</u> 32.3
HDL (mg/dL)	52.2 <u>+</u> 15.0	51.7 <u>+</u> 15.0	52.0 <u>+</u> 14.5	52.0 <u>+</u> 15.0
Glucose (mg/dL)	98.8 <u>+</u> 27.4	101.0 <u>+</u> 29.5	101.2 <u>+</u> 29.7	99.9 <u>+</u> 28.5
HbA1C (%)	6.6 <u>+</u> 1.6	6.5 <u>+</u> 1.5	6.4 <u>+</u> 1.5	6.5 <u>+</u> 1.6

Change from baseline after one year



MAYO CLINIC

ŢŢ

Univariate Analysis For the Prediction of Frequent Users

Term	Estimate	Std Error	t Ratio		Prob> t
Gender[Female]	1.0478503	0.12198	8.59		<.0001*
Baseline Weight	0.013892	0.002492	5.58		<.0001*
Age	0.052951	0.009829	5.39		<.0001*
Systolic BP, Baseline	-0.034422	0.008668	-3.97		<.0001*



Primary and Secondary Prevention Studies

Primary prevention:

- One site 500 individuals 3 months follow up
- Multiple sites 37,000 individuals follow up 1 year

Secondary prevention following ACS


- During the 3 months of cardiac rehabilitation
- During the 3 months following completion of the cardiac rehabilitation



Cardiac Rehabilitation and Mortality Impact After PCI


Mayo Clinic Study

- Patients undergoing PCI
- 1994-2008
- CR vs no CR
- 5-year death rates 45% lower for CR participants
- Benefit began in year 1 and persisted





Association between cardiac rehabilitation (CR) participation and mortality matched groups.



MAYO

CLINIC

Learn and Live | 3301614-28

Affordable Care Act (Section 3025) Readmission-Reductions Program

DRGs: CHF, AMI and Pneumonia Readmission rates exceed calculated average

Financial penalty applied to all Medicare admissions for subsequent year


 2013
 2014
 2015

 Penalty = 1%
 Penalty = 2%
 Penalty = 3%

 COPD; Knee and Hip Replacement

 ...and PCI and CABG?








Baseline Demographic Data

Category	CR+DHI (n=18)	CR (n=19)	Post CR+DHI (n=17)	Post CR (n=11)
Age, yrs	62.1 <u>+</u> 10.0	70.4 <u>+</u> 9.9	66.9 <u>+</u> 8.3	69.4 <u>+</u> 10.1
Male	[′] 3/18 (72.2%)	17/19 (89%)	11/15 (73%)	6/11 (66%)
*Weight, kg	92.1 <u>+</u> 17.5	90.7 <u>+</u> 18.8	95.5 <u>+</u> 22.9	86.8 <u>+</u> 19.1
BMI, kg/m²	30.1 <u>+</u> 4.6	30.6 <u>+</u> 5.6	30.4 <u>+</u> 4.9	29.9 <u>+</u> 6.3
**Systolic Blood Pressure, mmHg	124.8 <u>+</u> 12.3	123.6 <u>+</u> 13.8	127.5 <u>+</u> 16.6	124.0 <u>+</u> 16.9
Glucose, mg/dL	121.8 <u>+</u> 42.4	122.7 <u>+</u> 42.4	115.9 <u>+</u> 30.5	102.1 <u>+</u> 13.0
Total Cholesterol	185.2 <u>+</u> 44.0	173.8 <u>+</u> 51.8	167.7 <u>+</u> 34.3	137.1 <u>+</u> 33.0
LDL-Cholesterol, mg/dL	105.4 <u>+</u> 44.8	94.9 <u>+</u> 41.08	89.5 <u>+</u> 26.7	69.9 <u>+</u> 26.0
HDL-Cholesterol, mg/dL	43.8 <u>+</u> 15.4	51.1 <u>+</u> 18.9	53.9 <u>+</u> 23.6	47.5 <u>+</u> 14.0
Triglycerides, mg/dL	163.3 <u>+</u> 87.2	185.5 <u>+</u> 253.9	142.1 <u>+</u> 135.2	114.3 <u>+</u> 58.1
Current Smoking	3/18 (17%)	2/19 (11%)	0/14 (0%)	1/11 (11%)


ŢŢ

Use of DHI During CR Resulted in a Reduction in Risk Factor at 3 Months






Association Between Change in SBP and Usage Frequency





Use of DHI During CR Resulted in a Reduction in Hospitalization at 3 Months






Baseline Demographic Data


Category	CR+DHI (n=18)	CR (n=19)	Post CR+DHI (n=17)	Post CR (n=11)
Age, yrs	62.1 <u>+</u> 10.0	70.4 <u>+</u> 9.9	66.9 <u>+</u> 8.3	69.4 <u>+</u> 10.1
Male	13/18 (72.2%)	17/19 (89%)	11/15 (73%)	6/11 (66%)
*Weight, kg	92.1 <u>+</u> 17.5	90.7 <u>+</u> 18.8	95.5 <u>+</u> 22.9	86.8 <u>+</u> 19.1
BMI, kg/m²	30.1 <u>+</u> 4.6	30.6 <u>+</u> 5.6	30.4 <u>+</u> 4.9	29.9 <u>+</u> 6.3
**Systolic Blood Pressure, mmHg	124.8 <u>+</u> 12.3	123.6 <u>+</u> 13.8	127.5 <u>+</u> 16.6	124.0 <u>+</u> 16.9
Glucose, mg/dL	121.8 <u>+</u> 42.4	122.7 <u>+</u> 42.4	115.9 <u>+</u> 30.5	102.1 <u>+</u> 13.0
Total Cholesterol	185.2 <u>+</u> 44.0	173.8 <u>+</u> 51.8	167.7 <u>+</u> 34.3	137.1 <u>+</u> 33.0
LDL-Cholesterol, mg/dL	105.4 <u>+</u> 44.8	94.9 <u>+</u> 41.08	89.5 <u>+</u> 26.7	69.9 <u>+</u> 26.0
HDL-Cholesterol, mg/dL	43.8 <u>+</u> 15.4	51.1 <u>+</u> 18.9	53.9 <u>+</u> 23.6	47.5 <u>+</u> 14.0
Triglycerides, mg/dL	163.3 <u>+</u> 87.2	185.5 <u>+</u> 253.9	142.1 <u>+</u> 135.2	114.3 <u>+</u> 58.1
Current Smoking MAYO CLINIC	3/18 (17%)	2/19 (11%)	0/14 (0%)	1/11 (11%)

ᢉᠯ᠊᠋ᠮ

Use of DHI for 3 months following CR Resulted in a Reduction in Risk Factor at 6 Months



Reduction in Re-hospitalizations/ED Visits 3 months following completing CR




Post-CR + PHA Post-CR Alone




*p=0.04

©2013 MFMER | 3301614-37

Use of DHI Resulted in a Reduction in Rehospitalizations/ ED Visits



CVD Outcomes



Conclusions

- In primary prevention: A DHI-based can reduce CVD risk factors in a large cohort of communitydwelling employees
- CVD risk factor reduction occurs in a dosedependent fashion as those with more frequent use displayed significantly more gain
- Secondary prevention: The use of DHI reduces CV risk and re-hospitalization following ACS







State of Mobile Health

Criteria for a Successful Health Application

- Evidence/Guideline-Based
- User Friendly
- Incentive-Based
- Flexible operating platform able to be easily modified based on new scientific data and guidelines
- Interact with Social Media
- Wide Applicability and Distribution (i.e. smartphones)
- Not dependent on proximity to medical center

keep track of your body's biorhythms")

IMS Institute for Healthcare Informatics, 2013

tn

ely

he